articleTop 1% cited
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
Gynecologic Oncology · 2004 · Vol. 95(1) · pp. 1–8
Alan N. Gordon✉(Arizona Oncology)Margaret TondaSteven Sun(Johnson & Johnson (United States))Wayne Rackoff(Johnson & Johnson (United States))
Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesEndometrial and Cervical Cancer TreatmentsTopotecanMedicineDoxorubicinInternal medicineHazard ratioChemotherapyGastroenterologySurgeryRandomized controlled trialOncology
MeSH terms
AdultAgedAntibiotics, AntineoplasticAntineoplastic AgentsDoxorubicinFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateTopotecan
Citations
431
FWCI
26.84
field-weighted impact
References
19
Percentile
100%
vs. same field & year
Citations per year
Cited by
Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Gynecologic Oncology · 2008 · 369 citations
The resurgence of platinum-based cancer chemotherapy
Nature reviews. Cancer · 2007 · 4,639 citations
References
Cancer: Principles and Practice of Oncology.
Annals of Internal Medicine · 1991 · 8,541 citations
Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin
Drugs · 1997 · 477 citations
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
Gynecologic Oncology · 1990 · 391 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.